Dextroamphetamine

If the patient is not agitated, cyanosed nor imminently dying, a trial of methylphenidate Ritalin ; 510mg or dextroamphetamine Dexedrine ; 2.55.0mg once or twice daily in the morning may help. Tolerance develops to these drugs and may limit their role. A newer CNS stimulant, modafinil Alertec ; may be tried. Its mechanism of action is not entirely clear, but it has central 1-adrenergic receptor agonism. It also may have a different site of action in the hypothalamus rather than the cortex as in methylphenidate 5 ; . As such, its adverse effect profile is also different and lower. Although officially approved only for use in narcolepsy, it has been found helpful in cancer-related fatigue, in Alzheimer's disease and as an adjuvant in depression 6 ; . Dosage is 100200mg morning or divided at morning and noon.

Provide appropriate interventions as outlined under General Approach and in the Headache algorithm in Appendix A. If warranted, initiate analgesic therapy per protocol. A. Kiotsekoglou, R.S. Sharma, P.M. Elliott, W.J. McKenna, D. Pellerin. The Heart Hospital, London, United Kingdom Left ventricular outflow tract LVOT ; obstruction and diastolic dysfunction are responsible for dyspnoea in patients with hypertrophic obstructive cardiomyopathy HOCM ; . Surgical myectomy and percutaneous septal alcohol ablation are effective treatments to relieve obstruction in these patients. To assess the effect of surgical and percutaneous ; septal reduction therapy SRT ; on LV diastolic function, 59 HOCM patients were studied at baseline and 34 months after septal myectomy n 37 ; or alcohol ablation n 22 ; . There was a significant improvement in NYHA class and in peak oxygen consumption after SRT. LVOT pressure gradient was markedly reduced to a similar extend by both procedures. The ratio of early to late peak diastolic LV inflow velocities E A ; and the ratio of early diastolic LV inflow velocity to lateral mitral annular velocity E Ea ; significantly decreased after SRT 1.51.6 versus 0.90.8 and 179 versus 105 respectively ; . At baseline, 54% of patients had delayed relaxation and 35% showed a pseudonormal pattern on transmitral inflow recording. After SRT, 89% of patients showed delayed relaxation. 80% of patients with a restrictive LV filling pattern before SRT had pseudonormal or delayed relaxation after SRT. Left atrial area at end systole decreased form 338 to 266 cm2 , p 0.05. Total area of mitral regurgitant jet also significantly decreased. There was no correlation between the change in diastolic pattern, E A and E Ea ratios and the change in mitral regurgitation. There were no significant differences in the changes of LV diastolic function indices between septal myectomy and alcohol ablation patients. Conclusion: Echocardiographic diastolic function parameters improved after SRT in HOCM patients with similar changes after septal myectomy and septal alcohol ablation. These changes in diastolic parameters were not related to the decrease in mitral regurgitation. Improvement in LV relaxation and decrease in LA pressure after SRT may contribute to the clinical amelioration of the patients.
Attention deficit hyperactivity disorder ADHD ; ADHD is estimated to affect between 3% and 7% of children in the US. Often presenting with symptoms of inattention, impulsivity hyperactivity, or both, the sufferer can experience impaired functioning in social and educational settings with resultant educational and family disruption. In approximately 66% of children, symptoms will persist into adulthood with estimates of up to million adults in the US having ADHD. Since the launch of its first products for the management of ADHD DEXTROSTAT dextroamphetamine salt ; and ADDERALL ; , Shire has remained committed to the development of products for ADHD. The latest addition to the marketed ADHD portfolio is ADDERALL XR, a patented once-daily dosing formulation of ADDERALL that uses Shire Laboratories' MICROTROL drug delivery technology. Once-daily dosing offers a significant convenience to patients and caregivers, removing the need for duringschool or after-school treatment, and provides the potential for improved compliance. Largest-ever ADHD clinical trial Results from two key trials have contributed to the strong demand for ADDERALL XR. A multi-centre, randomised, double-blind, placebo controlled study published in the journal Pediatrics August 2002 ; , involving 584 children, concluded that one morning dose of ADDERALL XR was well-tolerated and effective at controlling symptoms of ADHD throughout the day. A second study, the largest-ever ADHD clinical trial the Long Acting Adderall Community Assessment Trial or LADD T study ; , was presented at the American Psychiatric Association Annual Meeting in Philadelphia, in 2002. Involving nearly 3, 000 children, the study demonstrated that ADDERALL XR significantly improves the hallmark symptoms of ADHD and the quality of life of children living with the condition. The most successful switch Launched in November 2001, ADDERALL XR has become one of the most widely prescribed ADHD treatments in the US. Over 4.5 million prescriptions have been written, and by the end of 2002 the product claimed 23.8% of the ADHD market in the US. This reflects the success in switching patients from the original immediate-release product to the once-daily brand. Underpinning the successful launch of ADDERALL XR Shire continues to promote awareness and understanding of ADHD to the general public. New strengths The addition of three new strengths of ADDERALL XR 5mg, 15mg, 25mg ; to the product range complements the existing strengths 10mg, 20mg and 30mg ; providing patients and clinicians with additional flexibility. Adult ADHD At the end of 2002 Shire filed a supplemental New Drug Application sNDA ; with the Food and Drug Administration FDA ; for use of ADDERALL XR in the treatment of adult ADHD. It is estimated that up to 8 million adults in the US have ADHD. However, this is a relatively underdeveloped market with only approximately 5% of those affected receiving treatment. This may result from limited awareness and diagnosis of ADHD in the adult population. ADHD pipeline SPD503, a novel formulation of a nonscheduled compound, entered phase III of clinical development in children in early 2003. Studies to assess its potential in adult ADHD patients are being designed. SPD473 is a mixed monoamine reuptake inhibitor. Its unique mode of action, affecting three neurotransmitters that may be implicated in ADHD noradrenaline, serotonin and dopamine ; makes this an interesting candidate for ADHD treatment. A phase II proof-ofconcept study in ADHD is planned for 2003. METHYPATCH is a recent acquisition to the Shire portfolio, and was filed with the FDA on 27 June 2002. Subject to regulatory approval it will be the first transdermal drug delivery based product offered for the treatment of ADHD.
Basic Core Formulary ADHD Narcolepsy MTF Costs System Costc e methylphenidate IR Ritalin, Methylin, generics ; ##TEXT##.10 ##TEXT##.39 Other Uniform Formulary Narcolepsy available for inclusion on MTF formularies dextroamphetamine ER Dexedrine Spansules, generic ; e ##TEXT##.78 .23 dextroamphetamine IR Dexedrine, Dextrostat, generics ; e ##TEXT##.15 ##TEXT##.43 mixed amphetamine salts, IR Adderall, generics ; e ##TEXT##.50 ##TEXT##.83 modafinil Provigil ; .34 .89 sodium oxybate Xyrem ; N A .78d Non-formulary Agents None.

Over the past few months I have made several presentations on both Chronic Disease Management and the Family Practice Oncology Network to a variety of physicians and allied health professionals across the country. There is no doubt that Chronic Disease Management is responsible for generating new interest and enthusiasm in what has commonly become known as "full service family practice". There is also new realization that cancer care can adopt many of the principles of CDM and that many cancers can be managed in this way. The Family Practice Oncology Network, having laid excellent groundwork in Continuing Medicine Education and the Preceptorship Program, is now moving into a new phase of practitioner engagement with redevelopment of the strategic plan and production of a "way forward" document. It was reassuring to see that what was presented across the country met with significant enthusiasm. We feel that in the next year we will see all of the groundwork translating into a more integrated and meaningful knowledge network and cancer management system for all family practitioners in BC and dextromethorphan.

Free Dextroamphetamine 1. Asherson P et al. Adult attention-deficit hyperactivity disorder: recognition and treatment in general adult psychiatry. Br J Psychiatry 2007; 190: 4-5 E ; 2. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 2005; 5: 525-39 R ; 3. Faraone SV et al. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006; 36: 159-65 MA ; 4. NICE. Technology Appraisal 98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder ADHD ; in children and adolescents guidance. London, 2006. G ; 5. NICE. nice page x?o 207034. Last accessed 15 02 07 Nutt DJ et al. Evidence-based guidelines for the management of attentiondeficit hyperactivity disorder in adolescents in transition to adult services and in adults. J Psychopharmacol 2007; 21: 10-41 G ; 7. Strattera atomoxetine ; , Dexedrine dexamfetamine ; , Concerta XL, Equasym, Equasym XL, and Ritalin all methylphenidate ; summary of product characteristics accessed via : emc.medicines emc. Last accessed 25 01 07 Michelson D et al. Atomoxetine in adults with ADHD: Two randomized, placebocontrolled studies. Biol Psychiatry 2003; 53: 110-2 RCT ; 9. Adler LA et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit hyperactivity disorder: an interim analysis. J Clin Psychiatry 2005; 66: 294-9 RCT ; 10. Adler L et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry 2006; 18: 107-13 RCT ; 11. Weiss M et al. A randomized double-blind trial of paroxetine and or dextroamphetamine and problem-focused therapy for attention-deficit hyperactivity disorder in adults. J Clin Psychiatry 2006; 67: 611-9 RCT ; 12. Paterson R et al. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 1999; 33: 494-502 RCT ; 13. Spencer T et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit hyperactivity disorder. Biol Psychiatry 2005; 57: 456-63 RCT ; 14. Biederman J et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention deficit hyperactivity disorder. Biol Psychiatry 2006; 59: 829-35 RCT ; 15. Faraone SV et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit hyperactivity disorder. J Clin Psychopharmacol 2004; 24: 24-9 MA ; 16. Simpson D et al. Atomoxetine, a review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004; 64: 205-22 R. Given that valproate doubles the serum level of lamotrigine, would it make sense to use a combination of the two drugs? Yes. There are a number of clinical reports on the usefulness of this two-drug combination for some psychiatric or epileptic disorders Pisani 1999, Morris 2000, Aldenkamp 2002, Cuadrado 2002, Thome - Souza 2003 ; However, please be aware that higher lamotrigine levels could be associated with increased toxicity and diamox. What is Dextroamphetamine Products manufactured by this brand name manufacturer in this drug entity are available for drug product selection under other brand and or generic names. p. 62 DESONIDE Added: 10-08-03 ; Added: 10-08-03 ; DESOXIMETASONE Added: 07-13-03 ; DEXTROAMPHETAMINE SULFATE Added: 08-18-03 ; lotion, topical 0.05% ointment, topical 0.05% cream, topical 0.25% tablet, oral 5, 10mg Altana Altana Clay-Park KV.

Dextroamphetamine oral Side effects. Adverse effects of large quantities of GH in adults include acromegaly with associated myopathy, peripheral neuropathy, glucose intolerance, increased plasma cholesterol and triglyceride concentrations, coronary artev disease, and cardiomyopathy.2, 27, 52, 54prepubescent athletes, In excessive quantities of GH result in gigantism. The musculoskeletal and cardiac effects associated with excessive GH use may be irreversible, even after discontinuation of the hormone. Moreover, needle sharing for intramuscular administration carries the risk of disease transmission. Regulation. Human GH, synthetic GH, and GH-releasing factors are all and dicloxacillin. Joseph aspirin-free , stadol , stadol ns , statex , sterapred , sterapred ds , strifon fort , sublimaze , subutex , sufenta , sufentanil , sular , sunitinib , surmontil , sustiva , sutent , synthroid , systen , t-phyl , tac 3 , tace , tacrolimus , tadalafil , talwin lactate , taminol , tamofen , tamofen obsolete ; , tamone , tamosin , tamoxen , tamoxifen , tamoxifen hexal , tanacof-xr , tanahist-pd , tarceva , targretin , tasigna , tasmar , tavist , tavist allergy , tavist-1 , taxol , taxotere , taztia xt , telithromycin , telmisartan , telzir , temazepam , tempol , tempra , tempra 1 , tempra 2 , tempra 3 , tempra quicklets , temsirolimus , tenex , teniposide , tenormin , terazosin , terry white chemists colour free paracetamol 1-5 years , terry white chemists colour free paracetamol infant drops , terry white chemists paracetamol , terry white chemists paracetamol colourfree children 5-12 years , terry white chemists tamoxifen , terry white chemists tramadol , teveten , thais , thaissept , thalidomide , thalitone , thalomid , theo-24 , theo-dur , theo-dur sprinkles , theo-time , theo-x , theobid , theocap , theochron , theoclear -130 , theoclear -260 , theoclear-80 , theolair , theolair-sr , theophylline , theophylline 24 hr extended release , theophylline extended release , theovent , thiothixene , thyroid desiccated , thyrolar-1 , thyrolar-1 2 , thyrolar-1 4 , thyrolar-2 , thyrolar-3 , tiagabine , tiazac , ticon , tigan , timolol , tindamax , tinidazole , tipranavir , tirosint , tizanidine , tofranil , tofranil-pm , tolcapone , toposar , toprol-xl , toremifene , torisel , torsemide , tramacort-d , tramadol , tramadol extended release , tramahexal , tramahexal sr , tramake , tramake insts , tramal , tramal sr , tramedo , trancopal , trandate , trandolapril , tranylcypromine , trazodone , triam-a , triam-forte , triamcinolone , triamcinolone acetonide , triamcinolone diacetate , triamcinolone hexacetonide , triamcot , triaminic allergy , triamonide 40 , triamterene , triazolam , tridil , trihexane , trihexyphenidyl , trilog , trilone , trimethaphan camsylate , trimethobenzamide , trimipramine , triostat , tripelennamine , triprolidine , triprolidine extended release , tristoject , truphylline , truxophyllin , tycolene , tykerb , tylenol , tylenol 8 hour caplet , tylenol 8 hour extended relief , tylenol 8 hour geltab , tylenol arthritis caplet , tylenol arthritis extended release , tylenol arthritis geltab , tylenol caplet , tylenol caplet extra strength , tylenol childrens , tylenol childrens paracetamol , tylenol extended release , tylenol extra strength , tylenol extra strength cool caplet , tylenol extra strength ez , tylenol gelcap extra strength , tylenol geltab extra strength , tylenol gotabs , tylenol infant , tylenol pbs , tylenol rapid release gelcap , tylenol regular strength , tylenol sore throat , tylenol sore throat daytime , tylenol suspension , u-tri-lone , ultiva , ultram , ultram er , umphamol , under ten care infant , uni-dur , uniphyl , uniserts , unisom , unithroid , univasc , uprima , urispas , uroxatral , vagifem , valdecoxib , valergen , valproic acid , valsartan , vanadom , vanatrip , vasotec , vazol , velcade , venlafaxine , venlafaxine extended release , vepesid , verapamil , verapamil 24 hour extended release , verapamil extended release , verelan , verelan , vesicare , viagra , vibra-tabs , vibramycin , vibramycin calcium , vibramycin hyclate , vibramycin monohydrate , viracept , visken , vitamin b6 , vitamin d , vitamin d , vitamin d2 , vitamin d3 , vitamin d3 1, 25 2 ; , vitamin d3 25 ; , vitapap , vitelle nestrex , vivactil , vivelle , vivelle-dot , vivelledot , vumon , wal-finate , welchol , wellbutrin , wellbutrin sr , wellbutrin xl , westhroid , xyzal , xyzall , your pharmacy childrens paracetamol colourfree 5-12 years , your pharmacy colourfree paracetamol age 1 month to 2 years , your pharmacy colourfree paracetamol children 1-5 years , your pharmacy paracetamol , zaleplon , zamadol , zamadol 24hr , zamadol melt , zamadol sr , zanaflex , zaponex , zarontin , zaroxolyn , zebeta , zemplar , zestril , ziconotide , ziprasidone , zoloft , zolpidem , zolpidem extended release , zonalon , zonegran , zonisamide , zumenon , zyban , zyban advantage pack , zydol , zydol sr , zydol xl , zymine , zymine xr , zyprexa , zyprexa zydis , zyrtec , zyvox , minor interactions aczone , adgan , adriamycin , adriamycin rdf , aldomet , amphetamine , anergan 50 , anestacaine , antinaus 50 , aromasin , articaine , azulfidine , azulfidine en-tabs , benzphetamine , bupivacaine , busulfan , busulfex , carbamazepine , carbamazepine extended release , carbatrol , carbocaine , carbocaine hcl , cataflam , ceenu , cevimeline , chirocaine , chlorpromazine , chlorpromazine extended release , cholestyramine , cholestyramine light , cimetidine , compazine , compazine spansule , compro , concerta , cozaar , cyclophosphamide , cyclophosphamide lyophilized , cytoxan , cytoxan lyophilized , dapsone topical , daytrana , desoxyn , desoxyn gradumet , dexedrine , dexedrine spansule , dexmethylphenidate , dexmethylphenidate extended release , dextroamphetamine , dextroamphetamine extended release , dextrostat , diclofenac , diclofenac potassium , diclofenac sodium , diclofenac sodium extended release , didrex , dilocaine , dofetilide , doxil , doxorubicin , doxorubicin liposomal , duranest-mpf , epitol , eplerenone , equetro , etidocaine , evening primrose , evening primrose oil , evoxac , exemestane , fenoprofen , fluoxetine , fluoxetine extended release , fluphenazine , fluphenazine decanoate , fluphenazine enanthate , fluphenazine hydrochloride , focalin , focalin xr , gingko , gingko biloba , ginkgo , ginkgo biloba , granisetron , inspra , kytril , l-caine , largon , levobupivacaine , levoprome , lidocaine , lidoject 1 , lidoject 2 , lisdexamfetamine , lomustine , losartan , lysodren , marcaine hcl , marcaine spinal , mellaril , mellaril-s , mepivacaine , mesoridazine , metadate cd , metadate er , methamphetamine , methamphetamine extended release , methdilazine , methimazole , methotrimeprazine , methyldopa , methylin , methylin er , methylphenidate , methylphenidate 24 hour extended release , methylphenidate extended release , mitotane , myleran , nalfon , naropin , naropin novaplus , naropin polyamp , naropin sdv , neosar , nervocaine , northyx , ormazine , oxcarbazepine , paroxetine , paroxetine extended release , paroxetine mesylate , paxil , paxil cr , pentazine , permitil , perphenazine , pexeva , phenacemide , phenadoz , phenazine 50 , phenergan , phenergan fortis , phenoject-50 , phenurone , polocaine , polocaine-mpf , prevalite , primrose oil , pro-med , prochlorperazine , prochlorperazine extended release , procot , prolixin , prolixin decanoate , prolixin enanthate , promacot , promazine , promethazine , promethegan , propafenone , propafenone extended release , propiomazine , prorex , prozac , prozac weekly , questran , questran light , rapiflux , rifadin , rifadin iv , rifampin , rimactane , ritalin , ritalin la , ritalin-sr , ropivacaine , rythmol , rythmol sr , sarafem , sensorcaine , sensorcaine-mpf , serentil , sparine , stelazine , sulfasalazine , sulfazine , tacaryl , tagamet , tagamet hb , tapazole , tegretol , tegretol xr , temaril , thiethylperazine , thioridazine , thorazine , tikosyn , topamax , topamax sprinkle , topiramate , torecan , trifluoperazine , triflupromazine , trilafon , trileptal , trimeprazine , truxacaine , uad caine , v-gan-25 , v-gan-50 , valerian , valerian root , voltaren , voltaren-xr , vyvanse , xylocaine dental cartridges , xylocaine duo-trach kit , xylocaine hcl , xylocaine hcl for spinal , xylocaine-mpf , hyoscyamine is known to interact with the following drugs: click on a link below to view drug-drug interactions with hyoscyamine. Azathioprine is an immunosuppressive drug used in the treatment of rheumatoid arthritis. It is also used in other autoimmune diseases e.g. systemic lupus erythematosus, vasculitis, inflammatory muscle disease, autoimmune hepatitis ; or as a steroid sparing agent and diflunisal.

Genes delivered by different vector systems have proven to be efficacious in pertinent animal models. A number of approaches have shown promise in clinical trials. At its core, the goal of nervous system gene therapy i.e., in vivo gene transfer ; is to improve upon traditional forms of drug delivery, e.g., reaching the brain side of the bloodbrain barrier; providing a prolonged drug gene effect; targeting drug gene activity to a desired anatomical site; reducing side effects; and freeing patients from repeat injections, external pumps, and hazardous procedures. In addition, certain gene products may not have a conventional drug equivalent, e.g., certain larger proteins may not be available as a recombinant product or a small-molecule analogue, but can be encoded and delivered as a therapeutic gene in a vector. To explore the potential of gene therapy for pain, we developed a therapeutic opioid gene for spinal delivery several years ago termed ``prepro endorphin'' pp EP ; 18 ; , which showed analgesic efficacy for up to 2 weeks when expressed by an adenovirus but was shut down by immunity against the vector 19 ; . Since then, new vector technology has become available for other applications. For instance, recombinant adeno-associated virus rAAV ; vectors were shown to mediate efficient in vivo gene transfer into nondividing cells, express transgenes in the long term, escape cellular immunity in most cases, and achieve reversal of pathology in various tissues, e.g., the retina. However, gene transfer by the IT route, i.e., by administration of vectors into the cerebrospinal fluid CSF ; by a lumbar puncture LP ; or other atraumatic technique, has remained challenging. Studies by other groups reported gene expression that was short-lived 2023 ; unless vector administration was repeated, which extended expression to only 6 weeks 24 found that only meningeal fibroblasts could be transduced 1921, 24 ; unless the vector was injected intraparenchymally 2527 and or relied on large-injection volumes, high-injection pressure, and hypertonic diluent 24, 28 ; . In our own experience, we found various nonviral vector systems ineffective if administered IT unpublished data ; , and we were similarly unable to detect transgene expression with conventional single-stranded rAAV serotype 2 29 ; . Therefore, we tested a variety of rAAV vector modifications, namely pseudotyping with capsids of different serotypes and the double-stranded, self-complementary rAAV scrAAV ; . Here we report that sc-rAAV serotype 8 sc-rAAV8 ; very efficiently and selectively transduced the primary sensory neurons in the dorsal root ganglia DRGs ; if administered IT, established long-term gene expression after a single vector. Public health: interventions delivered in primary and secondary schools to prevent and or reduce alcohol use by young people under 18 years old and dihydroergotamine. Tion on how this local environment compares with matrix environments which are relatively unperturbed. We report the results of experiments which show that a variety of spin labels have molecular motion nearly as fast 10C below the visual melting point as 10C above. Data from these experiments also allow the inference of melting points from plots of molecular motion vs. temperature. The sample used here allowed the comparison of spin label detectable "melts" and visual melts. This observation can be extended to allow the inference of physical state changes in the local environment of spin labels localized in the hydrocarbon zones of biological membranes. Has noted concerning Milton's depiction of the fall in Paradise Lost: "Between utterance and reception, Satan infuses the problematics of interpretation" Schwartz 65 ; . So, what secures truth here in Milton's invocation? In the beginning of this article, I noted the triple conjunction of opposites: 1 ; mighty wings gentle ; dove; 2 ; moving ; sitting; and 3 ; brooding impregnating. I suggest that these join in a dynamic tension to make Milton's imagery work toward preventing a stable image20 ; and thus toward preventing a clear assertion about the divine. Raman Selden and Peter Widdowson note a similar technique at work elsewhere in Paradise Lost and dilaudid. The most commonly used bioavailable form of dextroamphetamine is dextroamphetamine sulfate, which is a salt of d-amphetamine and dextroamphetamine. Data Cell Ltd., S C House, Van Wall Business Park, Maidenhead, Berks., SL6 4UB. Contact: Mr Giles Doe. Institute for Human Factors TNO, P.O.Box 23, 3769 ZG Soesterberg, The Netherlands. Contact: Dr A van Meeteren. National Illumination Committee of Great Britain, c o CIBSE, Delta House, 222 Balham High Road, London SW12 9BS. Dutch Working Group Ergophthalmology, c o NORI, Meibergdreef 47, 1105 BA, Amsterdam, The Netherlands. Contact: Dr T. J. van den Berg. Pilkington Optronics, Glascoed Rd., St Asaph, Denbighshire, LL17 0LL Contact: Mr J. Foley. Sowerby Research Centre, British Aerospace, P.O.Box 5, Filton, Bristol BS12 7QW. Contact: Dr KT rr and dionex.